Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease – A case series
- 8 July 2021
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (2), 429-436
- https://doi.org/10.1111/bcp.14978
Abstract
Chagas cardiomyopathy is the most prevalent non-ischaemic cardiomyopathy in Latin America, with high morbidity and mortality even today. Treatment of these patients is based on the use of medications for heart failure. This study evaluated a case series of patients with Chagas heart disease who used sacubitril/valsartan at a referral hospital for this disease in Brazil. After 6 months, there was a symptomatic improvement in these individuals assessed by the New York Heart Association (NYHA) functional class, with a 44.3% reduction in the absolute number of patients classified as III–IV in the period (P = 0.035), but without changes in the parameters on the echocardiogram for reverse ventricular remodelling. There was a high mortality rate and number of hospitalizations. These results emphasize the importance of studying the use of sacubitril/valsartan in Chagas heart disease to better describe its effectiveness considering the particularities of these individuals.This publication has 20 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Treatment of Chagas CardiomyopathyBioMed Research International, 2013
- Prognosis of patients with chronic systolic heart failure: Chagas disease versus systemic arterial hypertensionInternational Journal of Cardiology, 2013
- Left Ventricular Remodeling in Heart Failure: Current Concepts in Clinical Significance and AssessmentJACC: Cardiovascular Imaging, 2011
- β-Blocker Therapy and Mortality of Patients With Chagas CardiomyopathyCirculation: Heart Failure, 2010
- Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapyInternational Journal of Cardiology, 2008
- A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathyAmerican Heart Journal, 2007
- Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial InfarctionJournal of the American College of Cardiology, 2005
- Effects of metoprolol in chagasic patients with severe congestive heart failureInternational Journal of Cardiology, 2002
- Chagas cardiomyopathy and captoprilEuropean Heart Journal, 1992